Scope Fluidics SA Total Liabilities

Latest as of September 2025: zł26.24 Million PLN ≈ $7.22 Million USD

Scope Fluidics SA total liabilities. Based on the latest financial reports, Scope Fluidics SA (SCP) has total liabilities worth zł26.24 Million PLN (≈ $7.22 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scope Fluidics SA asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Scope Fluidics SA (2015–2024)

Total liabilities of Scope Fluidics SA from 2015 to 2024. This chart illustrates how Scope Fluidics SA's total liabilities have evolved over time, based on quarterly financial data.

Scope Fluidics SA Competitors by Total Liabilities

The table below lists competitors of Scope Fluidics SA ranked by their total liabilities.

Company Country Total Liabilities
ADDvise Group B
ST:ADDV-B
Sweden Skr1.81 Billion
Twinhead International Corp
TW:2364
Taiwan NT$1.09 Billion
Mosa Industrial Corp
TW:4564
Taiwan NT$2.47 Billion
Butterfly Gandhimathi Appliances Limited
NSE:BUTTERFLY
India Rs2.09 Billion
Feng Ching Metal
TWO:2061
Taiwan NT$535.52 Million
Iceland Seafood International hf.
IC:ICESEA
Iceland Ikr166.12 Million
Consolidated Finvest & Holdings Limited
NSE:CONSOFINVT
India Rs-11.59 Billion
RF Acquisition Corp II Unit
NASDAQ:RFAIU
USA $5.19 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Scope Fluidics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SCP current and non-current assets.

Liquidity & Leverage Metrics

Scope Fluidics SA Total Liabilities Ratios Explained

Scope Fluidics SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 13.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.23 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scope Fluidics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scope Fluidics SA (2015–2024)

The table below shows the annual total liabilities of Scope Fluidics SA from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 zł26.52 Million
≈ $7.30 Million
+28.99%
2023-12-31 zł20.56 Million
≈ $5.66 Million
+55.96%
2022-12-31 zł13.18 Million
≈ $3.63 Million
-65.45%
2021-12-31 zł38.15 Million
≈ $10.50 Million
+364.13%
2020-12-31 zł8.22 Million
≈ $2.26 Million
+14.39%
2019-12-31 zł7.19 Million
≈ $1.98 Million
+552.49%
2018-12-31 zł1.10 Million
≈ $303.10K
-39.28%
2017-12-31 zł1.81 Million
≈ $499.17K
+103.45%
2016-12-31 zł891.52K
≈ $245.36K
-67.80%
2015-12-31 zł2.77 Million
≈ $761.91K
--

About Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$108.48 Million
zł394.17 Million PLN
Market Cap Rank
#18696 Global
#141 in Poland
Share Price
zł144.60
Change (1 day)
-2.69%
52-Week Range
zł113.00 - zł156.40
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.